iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing
31 mars 2023 08h10 HE
|
iBio, Inc.
– Immuno-oncology candidate discovered using iBio’s AI epitope steering platform – – Expands Treg depletion franchise beyond IBIO-101 – BRYAN, Texas, March 31, 2023 (GLOBE NEWSWIRE) -- iBio, Inc....
iBio Announces MUC16 as its Latest Immune-Oncology Target Program
16 févr. 2023 16h48 HE
|
iBio, Inc.
- Company has directed antibodies against a specific region of MUC16 - - Potentially offers a differentiated and effective tool in the fight against cancer - BRYAN, Texas, Feb. 16, 2023 (GLOBE...
iBio Announces Issuance of U.S. Patent Covering AI-Engineered Epitope Discovery Engine
05 janv. 2023 08h00 HE
|
iBio, Inc.
BRYAN, Texas, Jan. 05, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced that the United...
iBio Announces Closing of $3.5 Million Underwritten Public Offering
09 déc. 2022 16h05 HE
|
iBio, Inc.
BRYAN, Texas, Dec. 09, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the closing of its...
iBio Announces Pricing of $3.5 Million Underwritten Public Offering
06 déc. 2022 23h27 HE
|
iBio, Inc.
BRYAN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the pricing of its...
iBio Announces Proposed Underwritten Public Offering
06 déc. 2022 16h01 HE
|
iBio, Inc.
BRYAN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced it intends to offer...
iBio to Participate in the JMP Securities Hematology and Oncology Summit
06 déc. 2022 08h00 HE
|
iBio, Inc.
BRYAN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today that its Chief...
iBio® to Showcase the RubrYc® Discovery Engine During Poster Presentations at Antibody Engineering & Therapeutics Conference 2022
05 déc. 2022 08h00 HE
|
iBio, Inc.
BRYAN, Texas, Dec. 05, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today it will present two...
iBio Announces CEO Departure
02 déc. 2022 16h30 HE
|
iBio, Inc.
BRYAN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the Board of...
iBio Accelerates Transformation to AI-Powered Biotech
03 nov. 2022 08h00 HE
|
iBio, Inc.
– Divesting CDMO business and cGMP biologics manufacturing facility – – Investing in pipeline of immuno-oncology assets and AI-based drug discovery platform – – Restructuring measures to result in...